mRNA Melanoma Vaccine Cuts Recurrence Risk by 42%

Adding the individualised mRNA therapy intismeran autogene to Merck's checkpoint inhibitor Keytruda reduced the risk of recurrence or death by 42 per cent in patients whose melanoma had been surgically removed, according to full phase 3 results presented at the European Society for Medical Oncology congress in Madrid on 24 October 2026. The hazard ratio for recurrence-free survival was 0.58, with a 95 per cent confidence interval of 0.45 to 0.75 and a two-sided p-value below 0.001.

Merck and Moderna, which are developing the therapy jointly, released the detailed data on 22 October, two days before the scheduled presentation, after partial figures were posted on social media and then removed. Reuters reported the same day that the trial, INTerpath-001, enrolled more than 1,100 patients with completely resected stage IIB to IV melanoma, and that the combination also cut the risk of the disease spreading to distant sites by 38 per cent. The analysis covers the first two years after treatment.

A vaccine built per patient, against 34 targets

Intismeran, previously known as V940 and mRNA-4157, is manufactured individually. Each patient's tumour is sequenced, and the therapy codes for 34 proteins found on that person's cancer cells but not on healthy tissue. The messenger RNA for those proteins is encased in a lipid particle, the same delivery method Moderna used for its Covid vaccine. Once cells begin producing the proteins, the immune system treats them as foreign and learns to attack cells carrying them.

Keytruda works by releasing a brake on the immune system; the vaccine aims to point it at a specific target. This is the first phase 3 trial to show the pair working together.

The size of the effect depended on when the clock started. In a pre-specified sensitivity analysis, benefit was larger after the first six months, once the immunisation regimen had been completed, with a piecewise hazard ratio of 0.42 and a confidence interval of 0.30 to 0.58. That is consistent with a therapy that needs time to generate a response, though it is a secondary analysis rather than the trial's primary result.

Why 42 per cent disappointed the market

The clinical reception and the market reception diverged sharply. Analysts had set 40 per cent as the level they were looking for, and the result cleared it, yet shares in both companies fell. The reason is the comparison with the earlier phase 2 trial, which had produced a roughly 49 per cent reduction. Trung Huynh, an analyst at RBC Capital Markets, wrote in a note that the phase 3 results were clinically meaningful and likely to support regulatory approval, but that the primary efficacy result landed at the low end of investor expectations.

David Berman, chief development officer at Moderna, told Time that he was "surprised by the fact that the results replicated the Phase 2 [study] so closely", noting that the phase 3 trial enrolled a much broader population than the earlier one.

The honest reading is that a hazard ratio of 0.58 in 1,100 patients is a more reliable number than the phase 2 figure, and less exciting for exactly that reason. A larger trial in a wider population producing a smaller effect is the ordinary shape of drug development, not a failure.

What two years cannot show

The trial reports recurrence-free and distant metastasis-free survival. It does not yet report overall survival, so there is no published evidence that patients given the combination live longer, only that their cancer returns later. For melanoma that distinction matters less than it does for some cancers, because recurrence after surgery is both common, most often within the first two years, and much harder to treat once the disease has reached the lung, liver or brain. More than half of patients who recur develop at least one distant metastasis. Merck's announcement notes more than 8,500 melanoma deaths in the United States in 2026.

Manufacturing is the other unresolved question. A therapy sequenced and built for one person is not a product that scales the way a pill does, and neither company has published the turnaround time or the cost per patient that a regulatory filing will eventually have to account for.